Blonanserin

Blonanserin (Lonasen) is a relatively new atypical antipsychotic commercialized by Dainippon Sumitomo Pharma in Japan and Korea for the treatment of schizophrenia. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms and excessive sedation and hypotension.

Blonanserin acts as a mixed 5-HT2 (Ki = 3.98 nM) and D2 receptor (Ki = 14.8 nM) antagonist. It also exerts some blockade of α1-adrenergic receptors (Ki = 56.3 nM) and has low affinity for the sigma receptor (IC50 = 286 nM). Blonanserin lacks significant affinity for numerous other sites including 5-HT1, 5-HT3, D1, α2-adrenergic, β-adrenergic, H1, mACh, and the monoamine transporters.